NCT00726427View on ClinicalTrials.gov

A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Healthy
Interventions
DRUG

AZD1656

Dose escalation to achieve maximum tolerated dose

DRUG

AZD1656

Oral single dose

Trial Locations (1)

Unknown

Research Site, Philadelphia

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY